Icoria and Rosetta Genomics, Alnylam Pharmaceuticals, Isis Pharmaceuticals and Max Planck Society, Sirna Therapeutics, and Benitec and Panomics | GenomeWeb

Icoria to Commercialize Rosetta Genomics’ MicroRNA Technology

Icoria said last week that it has signed an agreement to commercialize Rosetta Genomics’ MirChip microRNA detection and analysis technology.

Icoria said the commercialization will take place through its Paradigm Array Labs unit. The launch of MirChip is slated for Oct. 26 at the American Society of Human Genetics meeting in Toronto.

Alnylam, Isis License MicroRNA Technology from Max Planck

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.